European Association of Urology (EAU)

Hosted presentation of PRIMARY2 results at EAU26 Congress

Every year, roughly 750,000 men in the United States alone undergo prostate biopsies that turn out to be unnecessary. On March 13, 2026, researchers at the European Association of Urology Congress in London presented results from the PRIMARY2 trial showing that a scan using a molecule that binds to prostate cancer cells and makes them glow on imaging cut the need for biopsies nearly in half, without missing dangerous cancers.

Updated Yesterday